Gepubliceerd in:
19-05-2021
The association between the risk of developing type 2 diabetes mellitus and health-related quality of life: baseline results from the Dimini lifestyle intervention
Auteurs: Franziska Püschner, Sarah Wetzel, Dominika Urbanski-Rini, Nick Bertram, Monika Schliffke, Martin Göhl, Carsten Petersen, the Dimini Consortium
Gepubliceerd in: Quality of Life Research | Uitgave 12/2021
Log in om toegang te krijgenshare
DELEN
Deel dit onderdeel of sectie (kopieer de link)
-
Optie A:
-
Optie B:Deel de link per e-mail
Abstract
Purpose
The aim of the study was to analyse health-related quality of life (HRQoL) and its determinants in individuals with an increased risk of developing type 2 diabetes mellitus (T2D).
Methods
We used pseudonymized baseline data collected between 2018 and 2020 as part of the Dimini project in Hesse and Schleswig–Holstein. HRQoL was measured by the mental and the physical component score of the validated instrument Short Form 12 and descriptively analysed followed by multiple linear regression analysis.
Results
The Dimini population (n = 662) showed an average physical component score of 42.12 (SD 10.56) and a mental component score of 47.12 (SD 11.13). While men demonstrated both significantly higher physical and mental component scores than women, differences based on migration background were not observed. Younger age was associated with a higher level of the physical component score, whereas mental component scores linearly increased with age. Regarding indicators of T2D-risk, a significant influence of HbA1c on HRQoL was not confirmed. However, physical component scores are negatively related to Findrisk scores and BMI. Finally, study participants living alone and those with a handicap reported lower levels of HRQoL.
Conclusion
Compared with a representative sample of the general German population (DEGS1), Dimini participants were characterized by a lower average HRQoL. The analysis showed a higher vulnerability to an impaired HRQoL within certain subgroups of the population and among participants with relatively higher levels of T2D-risk. As a result, tailored healthcare interventions are required to reach these target groups.
Trial Registration Number: ClinicalTrials.gov ID NCT03482674.
